Jim Cramer: Buy Six Flags, Seattle Genetics, But Sell Oracle and These 2 Stocks
Jim Cramer made the following calls on July 1st, 2013. What do you think about his picks?
Six Flags Entertainment Corp. (NYSE:SIX): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on June 10, 2013. The stock’s 52-week high is $40.31, and its 52-week low is $26.24.
After surviving bankruptcy court and undergoing a $1.5 billion dollar debt restructuring, Six Flags ins trying to take advantage of the summer months and a slowly recovering U.S. economy. The company offers a 5 percent dividend, and moreover, has shown 10.7 percent growth over the last 3 years. The summer months also represents the majority of its sales, bringing in 71 percent of its revenue during the hot season.
Seattle Genetics Inc. (NASDAQ:SGEN): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on April 4, 2013. The stock’s 52-week high is $39.00, and its 52-week low is $21.05.
Bayer (BAYRY) has recently acquired the rights to Seattle’s auristatin-based antibody-drug conjugate as well as several antibodies to multiple oncology targets. More impressively, the company’s first test of the drug Adcetris on patients with relapsed or refractory Hodgkin lymphoma found that 26 out of 33 patients went into complete remission. The company has now move forward with phase II testing.
Oracle Corp. (NASDAQ:ORCL): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Buy on December 19, 2012. The stock’s 52-week high is $36.43, and its 52-week low is $28.61.
Oracle has recently undertaken a bond offering denominated in euros. It plans to use the cash raised for general purposes, from paying dividends, to future acquisitions. The company also rolled out a new data storage system which boasts the capability of reducing administration, tuning, and provisioning by up to 65 percent. For a more complete list of features associated with the new database, see here.
Trius Therapeutics, Inc. (NASDAQ:TSRX): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Buy on May 3, 2013. The stock’s 52-week high is $9.25, and its 52-week low is $4.41.
According to a new report, Trius’ experimental drug, tedizolid phosphate, or TR-701, “does not interact with monamine oxidase, or MAO. MAO is an enzyme involved in the regulation of neurotransmitters such as serotonin, norepinephrine and dopamine, and its inhibition can lead to serious drug-drug interactions.” This paves the way for the drug to interact with a variety of existing drugs, including anti-depressants. There’s also talk of Cubist (NASDAQ:CBST) acquiring Trius, as the company is in the market for an acquisition.
Pengrowth Energy Trust (NYSE:PGH): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Sell on February 27, 2013. The stock’s 52-week high is $7.49, and its 52-week low is $3.82.
While Cramer was bearish on Pengrowth, the company does have a massive dividend at over 9 percent. The company also undertook a project this year, the Lindbergh thermal bitumen project, which was expected to yield 12,500 barrels of bitumen per day.
Don’t Miss: Ford Is Adding Flair to the Hybrid Market.